FDA's drug short­ages leader wants com­pa­nies to start re­port­ing in­creas­es in de­mand

It is no se­cret that drug short­ages have been preva­lent in 2022. Sev­er­al ma­jor drug prod­ucts, such as amox­i­cillin and Adder­all, have been in short sup­ply for sev­er­al months and have led to mem­bers of Con­gress ap­ply­ing pres­sure on the FDA and HHS to re­solve the sit­u­a­tion.

Speak­ing at a we­bi­nar host­ed by the Al­liance for a Stronger FDA, Va­lerie Jensen, the as­so­ciate di­rec­tor of the FDA’s Drug Short­age Staff, not­ed both the rise in qual­i­ty-re­lat­ed is­sues and in­creased de­mand for some prod­ucts. She called on com­pa­nies to re­port such de­mand in­creas­es, even though they are not cur­rent­ly re­quired to do so.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.